Stratify Genomics, a San Diego, CA-based developer of genetic testing for cancer risk, raised $2.2m in a third seed funding.
The company will use the funds to achieve further sales and commercial partnerships.
Founded by Dr. Karim Kader, head of Urologic Oncology at UC San Diego, and led by Martyn Gross, President, Stratify Genomics specializes in cancer risk testing for the general population, using proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency.
Last year, the company has launched its flagship product Prompt Prostate Genetic Score (PGS), which provides lifetime risk assessment for prostate cancer and offers decision tools for recommending screening frequency.
Stratify Genomics was initially founded and funded by oncologists with the purpose of preventing cancer on the largest scale.